1 November 2022 01:32 p.m. All figures in US dollars. The profits announced by Harmony Biosciences Holdings Inc in the third quarter were higher than the Refinitiv mean estimate of profits. The company reported profits of $1.44 per share, $1.61 higher than the same quarter last year when the company reported EPS of -17 cents. Profits of 13 cents per share were anticipated by the seven analysts providing estimates for the quarter. Wall Street expected results to range from -4 cents to 44 cents per share, with a forecasted mean of 13 cents per share. The company reported revenue of $117.21 million, which is higher than the estimated $113.54 million. RECOMMENDATIONS * The consensus recommendation for the company is "Buy". * The average consensus recommendation for the pharmaceuticals peer group is also "Buy". FORECAST CHANGES * Eight analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There was no change to the number of estimates. YEAR OVER YEAR * The company reported an increase in revenue to $117.21 million from $80.73 million in the same quarter last year. * Previous quarterly performance (using earnings preferred measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Jun. 30 2022 0.44 0.39 Missed Mar. 31 2022 0.29 0.51 Beat Dec. 31 2021 0.36 0.38 Beat Sep. 30 2021 0.29 -0.17 Missed This summary was machine generated from Refinitiv data November 1 at 01:32 p.m.